Albany Molecular Research Overview
Albany Molecular Research (AMRI) has a ROE of -18.85%, below the sector sector average of -5.84%.
Get informed when a big investor buys or sells
+ Follow-18.85%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for AMRI is -18.85%. That is below the sector sector average of -5.84%. Investors often review this figure alongside Albany Molecular Research's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, AMRI currently prints -18.85% for ROE, while the sector average sits near -5.84%. That is roughly 222.6% below the sector mean. Large gaps often invite a closer look at Albany Molecular Research's growth, margins, and balance sheet.
Return on Equity shows how effectively Albany Molecular Research converts resources into returns. At -18.85%, AMRI may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting AMRI's ROE (-18.85%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
